# Submission rejected

## DRAFT REJECTED

**SPAR verdict:** `reject_critical` (3-0 unanimous reject).

## Proposed thesis (rejected)

> Therapies that inhibit aging biology, such as caloric restriction, metformin, senolytics, or rapalogs, may slow the development and progression of disease and functional decline in humans.

## Panel reviews

### `evidence_auditor` — `reject` (score 1)

The submission contains a critical failure in the citation trace. The alias_match for claim C003 resolves the term 'Therapies' (referring to caloric restriction, metformin, senolytics, or rapalogs) to 'LUMATEPERONE'. Lumateperone is an antipsychotic medication and has no biological or pharmacological relationship to the aging-inhibiting therapies mentioned in the claim. This represents a complete failure of the trace and an invalid mapping of evidence to the claim.

**Flagged claims:** C003

### `domain_skeptic` — `reject` (score 1)

The submission suffers from a catastrophic failure in domain alignment and evidence mapping. The thesis claims that aging-inhibiting therapies (metformin, rapalogs, etc.) may slow functional decline in humans, yet the citation trace reveals that the supporting evidence [ref=0] actually refers to 'LUMATEPERONE'. Lumateperone is an atypical antipsychotic used for schizophrenia and bipolar depression; it is not a caloric restriction mimetic, a senolytic, or a rapalog, nor is it an established therapy for 'inhibiting aging biology'.

Furthermore, the claim is framed as a broad generalization across multiple distinct pharmacological classes (metformin vs. senolytics) based on a single, irrelevant reference. This is a textbook case of off-topic drift and mechanism inflation, where a drug for psychiatric disorders is being used to support a sweeping conclusion about human longevity and systemic disease progression.

**Flagged claims:** C003

### `final_judge` — `reject` (score 1)

The submission is fundamentally flawed due to a catastrophic failure in the citation trace. Both the Evidence Auditor and the Domain Skeptic correctly identified that the evidence provided to support the claim regarding aging-inhibiting therapies (metformin, rapalogs, etc.) actually refers to Lumateperone, an antipsychotic medication. There is no pharmacological or biological overlap between an atypical antipsychotic and the mechanisms of caloric restriction or senolytics.

Because the supporting evidence is entirely irrelevant to the thesis, the claim is unsupported. The mapping of 'Therapies' to 'LUMATEPERONE' in the alias match is a critical error that invalidates the entire submission. I align with both previous reviewers in rejecting this submission on the grounds of evidence misalignment and domain inaccuracy.

**Flagged claims:** C003
